A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors - Tolcher, Anthony W.; Rodrigueza, Wendi V.; Rasco, Drew W.; Patnaik, Amita; Papadopoulos, Kyriakos P.; Amaya, Alex; Moore, Timothy D.; Gaylor, Shari K.; Bisgaier, Charles L.; Sooch, Mina P.; Woolliscroft, Michael J.; Messmann, Richard A. (Cancer chemotherapy and pharmacology, 2014)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic agents; Biological and medical sciences; Cancer Research; DNA - antagonists & inhibitors; Female; Humans; Liposomes - administration & dosage; Male; Maximum Tolerated Dose; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Molecular Targeted Therapy; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - metabolism; Neoplasms - pathology; Oligodeoxyribonucleotides - administration & dosage; Oligonucleotides - administration & dosage; Oligonucleotides - adverse effects; Oligonucleotides - pharmacokinetics; Oncology; Original; Original Article; Pharmacology. Drug treatments; Pharmacology/Toxicology; Proto-Oncogene Proteins c-bcl-2 - genetics; Treatment Outcome; Tumors; BCL2; Liposome; DNAi; PNT2258; Phase I; Deoxyribonucleic acid inhibitor; Human; Solid tumor; Targeting; Drug carrier; Malignant tumor; Target; DNA; C-Onc gene; Phase I trial; Advanced stage; Inhibitor; Protooncogene; Cancer